Example: Heart Attack

Clinical Trials on Neisseria Meningitidis Infection

Total 130 results

NCT04502693

Recruiting

Study to Assess Effectiveness of GlaxoSmithKline's (GSK's) Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults.

Conditions: Infections, Meningococcal
NCT04398849

Not yet recruiting

Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)

Conditions: Gonorrhea; Meningococcal Disease
NCT04358731

Recruiting

Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age

Conditions: Vaccine for Meningococcal Disease
NCT04318548

Recruiting

Study to Assess the Immunogenicity and Safety of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Conditions: Infections, Meningococcal
NCT04239430

Not yet recruiting

Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study

Conditions: HIV/AIDS; Meningococcal Disease
NCT04184336

Recruiting

Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada

Conditions: Invasive Meningococcal Disease
NCT04094883

Recruiting

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine

Conditions: Neisseria Gonorrhoeae Infection
NCT04023929

Not yet recruiting

Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays

Conditions: Pertussis; Meningococcal Disease; Prematurity
NCT03798574

Recruiting

The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults

Conditions: Meningococcal Infections; Neisseria Meningitis Sepsis; Neisseria Infection
NCT03694405

Active, not recruiting

Adolescent MenACWY Booster Study

Conditions: Meningococcal Disease, Invasive
NCT03652610

Completed

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age

Conditions: Infections, Meningococcal
NCT03493919

Recruiting

A Sourcing Study to Collect Human Blood Samples From Healthy Adults

Conditions: Meningitis, Meningococcal
NCT03433482

Completed

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age

Conditions: Meningitis, Meningococcal
NCT03378258

Completed

Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.

Conditions: Meningitis, Meningococcal; Meningococcal Sepsis; Meningococcal Disease; Meningococcal Infections; Sepsis; Meningitis
NCT03125616

Active, not recruiting

Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B

Conditions: Prematurity; Vaccination; Meningococcal Disease
NCT03089086

Completed

South Australian Meningococcal B Vaccine Herd Immunity Study

Conditions: Meningococcal Disease
NCT02986854

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Conditions: Infections, Meningococcal
NCT02946385

Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Conditions: Infections, Meningococcal
NCT02844088

Completed

Evaluation of Vaccinal and Natural Immunity Against Meningococcus C

Conditions: Prevention of Meningococcus C Infections
NCT02811120

Completed

PRIME Follow up - Quadri Meningo Vacinees

Conditions: Meningococcal Disease
NCT02727465

Withdrawn

Host-pathogen Interactions in Meningococcal Disease: Finding the Key That Fits the Lock

Conditions: Meningitis
NCT02569632

Unknown status

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

Conditions: Meningococcal Infections
NCT02531698

Completed

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

Conditions: MENINGOCOCCAL INFECTION
NCT02451514

Completed

A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)

Conditions: Meningococcal Disease; Infections, Meningococcal
NCT02398396

Active, not recruiting

Investigating Meningococcal Vaccines in Adults

Conditions: Meningococcal Vaccines; Meningococcal Infections; Neisseria Meningitidis; Factor H-binding Protein, Neisseria Meningitidi
NCT02287688

Completed

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study

Conditions: Meningococcal Disease; Infections, Meningococcal
NCT02285777

Completed

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Conditions: Meningococcal Disease
NCT02223637

Completed

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry

Conditions: Meningococcal Disease; Pregnancy; Infections, Meningococcal
NCT02173704

Completed

Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.

Conditions: Meningococcal Disease; Infections, Meningococcal
NCT02141516

Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

Conditions: Meningococcal Disease
NCT02140762

Completed

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Conditions: Meningococcal Disease
NCT01994629

Completed

Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

Conditions: Meningococcal Disease
NCT01992536

Completed

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Conditions: Meningococcal Disease
NCT01984125

Completed

Testing the Use of Prompts to Increase Adolescent Immunization Rates

Conditions: Vaccine Preventable Diseases; Meningococcal Disease; Human Papillomavirus; Pertussis; Influenza
NCT01973218

Completed

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

Conditions: Meningococcal Disease
NCT01911221

Completed

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Conditions: Prevention of the Meningococcal Disease
NCT01896596

Completed

Hepatitis B Vaccination in Infants

Conditions: Meningococcal Disease; Pneumococcal Disease; Haemophilus Influenzae Serotype b Disease; Diphtheria, Tetanus and Pertussis; Hepatitis b
NCT01839175

Completed

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Conditions: Neisseria Meningitidis; Bacterial Infections; Virus Diseases
NCT01839188

Completed

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Conditions: Neisseria Meningitidis; Bacterial Infections; Virus Diseases
NCT01823536

Completed

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Conditions: Meningococcal Disease
NCT01808365

Completed

N. Meningitidis Carriage Study

Conditions: Infections, Meningococcal
NCT01782066

Completed

Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines

Conditions: Meningococcal Disease
NCT01766206

Completed

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

Conditions: Meningococcal Disease
NCT01732627

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Conditions: Meningitis; Meningococcal Meningitis; Meningococcal Infections; Invasive Meningococcal Disease
NCT01730391

Completed

Neisseria Meningitidis Burden of Disease Study

Conditions: Streptococcus Pneumoniae; Neisseria Meningitidis; Haemophilus Influenzae
NCT01725217

Completed

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia

Conditions: Meningococcal Disease
NCT01717638

Completed

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Conditions: Meningococcal Disease; Meningococcal Meningitis
NCT01705379

Withdrawn

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older

Conditions: Meningococcal Disease
NCT01682876

Completed

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

Conditions: Meningococcal Disease; Infections, Meningococcal
NCT01642589

Completed

Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea

Conditions: Meningitis; Meningococcal Disease

COOKIE SETTINGS

Clinical Trials on Neisseria Meningitidis Infection